Zobrazeno 1 - 10 of 54 pro vyhledávání: '"T. Grasshoff"'
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Prospective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core biopsy proven axillary involvement (cN+)
Autor: C. Seiberling, T. Kuehn, Johannes Holtschmidt, S.-T. Graßhoff, Mattea Reinisch, A. Rüland, D Schindowski, J. Lubitz, E. Traut, S. Kuemmel, V. Hanf, Jörg Heil, C. Ankel, H. Harrach, P. Deuschle
Publikováno v: Annals of Oncology. 30:v56
Background As part of de-escalating strategies of the axillary treatment in lymph node (LN) positive BC pts, TAD was introduced (Caudle et al., JCO 2016). Despite this very interesting approach, some important aspects regarding the clinical feasibili
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eb7f9f3c64c784e5c1c743faa7571b78
https://doi.org/10.1093/annonc/mdz240.003
Zobrazit plný text záznamu
7
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
Autor: H. U. Ulmer, J. Steffen, S. Loibl, Ralph M. Wirtz, I. Baumann, G. von Minckwitz, Carsten Denkert, Georg Heinrich, Silvia Darb-Esfahani, C. von Toerne, G Hoffmann, B. M. Müller, S. T. Grasshoff, Ralf Kronenwett, Aurelia Noske, Marc Roller
Publikováno v: Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, Springer Verlag, 2010, 126 (1), pp.109-117. ⟨10.1007/s10549-010-1316-y⟩
International audience; Human epidermal growth factor receptor 2 (HER2) testing is an essential part of pathological assessment in breast cancer patients, as HER2 provides not only prognostic but also predictive information on response to targeted th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65cf78c4b5032723e45e380861bc0a29
https://doi.org/10.1007/s10549-010-1316-y
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)
Autor: G. von Minckwitz, S. Loibl, M. Untch, H. Eidtmann, M. Rezai, P.A. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. Hanusch, J. Huober, C. Solbach, C. Jackisch, G. Kunz, J.U. Blohmer, M. Hauschild, T. Fehm, V. Nekljudova, B. Gerber, K. Gnauert, B. Heinrich, T. Prätz, U. Groh, H. Tanzer, C. Villena, A. Tulusan, B. Liedtke, J.-U. Blohmer, C. Mau, J. Potenberg, J. Schilling, M. Just, E. Weiss, U. Bückner, M. Wolfgarten, R. Lorenz, G. Doering, S. Feidicker, P. Krabisch, U. Deichert, D. Augustin, K. Kast, C. Nestle-Krämling, C. Höß, J. Terhaag, P. Fasching, P. Staib, B. Aktas, T. Kühn, F. Khandan, V. Möbus, E. Stickeler, G. Heinrich, H. Wagner, A. Abdallah, T. Dewitz, G. Emons, A. Belau, V. Rethwisch, T. Lantzsch, C. Thomssen, U. Mattner, A. Nugent, V. Müller, T. Noesselt, F. Holms, T. Müller, J.-U. Deuker, D. Strumberg, C. Uleer, E. Solomayer, I. Runnebaum, H. Link, O. Tomé, H.-U. Ulmer, B. Conrad, G. Feisel-Schwickardi, C. Schumacher, T. Steinmetz, I. Bauerfeind, S. Kremers, D. Langanke, U. Kullmer, A. Ober, D. Fischer, A. Kohls, W. Weikel, J. Bischoff, K. Freese, M. Schmidt, W. Wiest, M. Sütterlin, M. Dietrich, M. Grießhammer, D.-M. Burgmann, B. Rack, C. Salat, D. Sattler, J. Tio, E. von Abel, B. Christensen, U. Burkamp, C.-H. Köhne, W. Meinerz, S.-T. Graßhoff, T. Decker, F. Overkamp, I. Thalmann, A. Sallmann, T. Beck, T. Reimer, G. Bartzke, M. Deryal, M. Weigel, P. Weder, C.-C. Steffens, S. Lemster, A. Stefek, F. Ruhland, M. Hofmann, J. Schuster, W. Simon, U. Kronawitter, M. Clemens, W. Janni, K. Latos, W. Bauer, A. Roßmann, L. Bauer, D. Lampe, V. Heyl, G. Hoffmann, F. Lorenz-Salehi, J. Hackmann, R. Schlag
Background The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline–taxane–based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative brea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd0d0889abbaa45ea11c291b5de85e20
https://www.ncbi.nlm.nih.gov/pubmed/25223482
Zobrazit plný text záznamu
10
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer
Autor: Klaus Baumann, S. Loibl, Antje Belau, H. Eidtmann, Keyur Mehta, Manfred Dietel, S. T. Grasshoff, C. Thommsen, Hans Tesch, Hans-Juergen Holzhausen, G. von Minckwitz, Bruno Valentin Sinn, G Hoffmann, Carsten Denkert, Ralf Kronenwett, Silvia Darb-Esfahani
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 24(9)
Background: Mucin-1 (MUC1) is a promising antigen for the development of tumor vaccines. We evaluated the frequency of MUC1 expression and its impact on therapy response and survival after neoadjuvant chemotherapy for breast cancer. Patients and meth
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e875f11d93f199a5b6deac041e309c93
https://pubmed.ncbi.nlm.nih.gov/23661292
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje